Allergex 2

Quick links to important sections

Allergex 2

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allergex 2

Quick Facts

Property Description
Active Ingredient Chlorpheniramine Maleate
Form Tablet, Syrup, Liquid
Pharmacological Class First-Generation Antihistamine
Common Use Symptomatic allergic relief
Origin Synthetic Alkylamine Derivative

Chlorpheniramine Maleate: Identity and Classification

Allergex 2 is a pharmaceutical preparation classified as a first-generation antihistamine, whose identity is fundamentally defined by its active ingredient, Chlorpheniramine Maleate. This core compound, also known formally as Chlorphenamine, is a synthetic alkylamine derivative that functions as a classic Histamine H1-receptor antagonist. Unlike second-generation agents, the pharmacological properties of Chlorpheniramine Maleate are clinically recognized for their effectiveness in mitigating acute allergic symptoms. The medication is an oral preparation typically marketed as a single-ingredient product, a characteristic that allows for precise targeting of histamine-mediated responses.

Composition, Form, and General Purpose

Chlorpheniramine Maleate is combined with standard pharmaceutical vehicles, consisting of either solid excipients for the tablet form or an aqueous solution base for the syrup or liquid form. This availability in multiple dosage forms provides flexibility for the target patient population, which includes both adults and children, differentiating its utility as a primary, accessible allergy solution. The general purpose of this synthetic compound is to relieve common allergic symptoms. By acting as an H1-receptor blocker, the medication is designed to provide symptomatic relief. This H1-receptor blockade is broadly useful for mitigating discomfort arising from typical histamine-mediated reactions, such as itching and swelling.

What side effects are possible with Allergex 2?

Possible Side Effects and Safety Information

Regulatory authorities classify the potential adverse effects of Chlorpheniramine Maleate (Allergex 2) based on frequency and the body system affected. The most frequently documented effects are related to the central nervous system (CNS) and anticholinergic activity, which are typical for this class of medicine.

Frequency Classification Documented Effects
Very Common Sedation, Somnolence (Drowsiness)
Common Dizziness, Disturbance in attention, Coordination abnormal, Dry mouth, Fatigue

Adverse reactions are grouped by System-Organ Class (SOC) in official labeling. CNS effects are common, while Gastrointestinal Disorders such as nausea and vomiting, and Eye Disorders like blurred vision, are also listed. Rare, but serious, adverse reactions include Anaphylactic Reactions and various Blood Dyscrasias (disorders of the blood and lymphatic system), such as anemia and thrombocytopenia.

Safety Considerations for Specific Populations

Official safety documents note specific considerations for certain patient groups. Older adults may face increased susceptibility to anticholinergic effects (e.g., urinary retention) and CNS effects (confusion, sedation). In children, there is a documented potential for the rare occurrence of paradoxical excitation, characterized by restlessness or tremors. Furthermore, the drug’s clearance may be reduced in patients with hepatic or renal impairment, potentially increasing the risk of adverse effects.

CNS effects are generally more pronounced at the initiation of treatment and are directly related to the administered dose. The medicine is contraindicated in neonates/premature infants, in patients with lower respiratory tract symptoms (including acute asthma), and for those concurrently using Monoamine Oxidase Inhibitors (MAOIs), as documented in regulatory safety constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

Chlorpheniramine maleate (Allergex 2) overdosage is a serious event that may be fatal, especially in infants and children. Immediate medical attention is required. If overdosage is suspected, contact a poison control center, emergency services, or proceed to the nearest emergency room, even if no symptoms are immediately noticeable.

Overdose manifestations can affect the Central Nervous System (CNS) and cardiovascular system, and may initially present differently in children versus adults.

Population Documented Overdose Presentations
Children/Infants CNS stimulation: excitement, hallucinations, impaired balance (ataxia), muscle tremor, and convulsions. Antimuscarinic effects include dilated pupils, flushed face, dry mouth, and hyperpyrexia (high fever).
Adults Primarily CNS depression: drowsiness, coma, and convulsions. Low blood pressure (hypotension) may also occur.

Serious complications of overdose, which can progress rapidly, include deepening coma, cardiorespiratory collapse, and death. Elderly patients may be particularly susceptible to the CNS depression and hypotensive effects. Always provide the healthcare provider with the name of the product, the amount taken, and the time of ingestion.

Therapeutic Uses of Allergex 2

Quick Facts

  • Main Use: Temporary relief of symptoms associated with allergic reactions.
  • Benefits: Helps manage allergic rhinitis, urticaria (hives), and related itching.
  • Therapeutic Role: A treatment option within the antihistamine class.

Allergex 2 is a medication indicated to provide temporary relief of symptoms associated with a range of allergic conditions. It is frequently employed in the management of allergic rhinitis, commonly known as hay fever. This can help alleviate complaints such as sneezing, runny nose (rhinorrhea), and itching of the nose and throat.

It is also a treatment option for skin-related allergic manifestations, including chronic idiopathic urticaria (hives) and certain other allergic dermatoses (skin reactions). The drug may help manage the associated symptoms of itching, swelling (angioedema), and rash.

As a widely used antihistamine, Allergex 2 is part of a therapeutic class that addresses conditions mediated by the body's release of histamine. This medication is available for use to help control symptoms related to seasonal and perennial allergies.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Allergex 2

Allergex 2 (Chlorpheniramine Maleate) has specific population eligibility rules defined by government regulatory documents. The medicine is generally permitted for use in adults, adolescents, and children aged 6 years and older. Use is explicitly contraindicated in several populations.


Absolute Contraindications

Patients must not use this medicine if they have a known hypersensitivity to any component or if they are currently taking Monoamine Oxidase Inhibitors (MAOIs), or have stopped MAOI therapy within the last 14 days. The medicine is also contraindicated for premature infants and neonates, and patients with narrow-angle glaucoma or conditions causing urinary retention.


Restrictions and Caution

Use is generally not recommended for children under six years of age (for most oral products). Special caution is required for older adults due to increased risk of neurological effects, and for patients with severe hepatic or renal impairment. Furthermore, the medicine is not recommended during breastfeeding or in the third trimester of pregnancy. Caution is also specified for patients with comorbidities such as epilepsy, asthma, or thyrotoxicosis.

What should I know about interactions with other medicines?

The interaction profile of Chlorpheniramine Maleate is strictly defined by government regulatory documents based on potential pharmacodynamic and pharmacokinetic effects with other substances.

Official Interaction Statements

Classification Interacting Substance / Category Documented Interaction Statement
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Prohibited co-administration due to intensification of anticholinergic and Central Nervous System (CNS) depressant effects, and inhibited metabolism.
Pharmacodynamic CNS Depressants (e.g., Sedatives, Opioid Analgesics) Concurrent use results in additive CNS depressant effects.
Pharmacodynamic Alcohol Documented interaction that results in additive CNS depressant effects.
Pharmacodynamic Anticholinergic Drugs Co-administration may lead to an intensification of anticholinergic effects.
Pharmacokinetic CYP2D6 Inhibitors Inhibition of the CYP2D6 enzyme may increase the plasma concentration and systemic exposure of Chlorpheniramine Maleate.
Pharmacokinetic Phenytoin Documented interaction that alters phenytoin metabolism, resulting in the reduced clearance of phenytoin.

Population-Specific Interaction Notes

An official caution notes that elderly patients may have a greater susceptibility to the anticholinergic effects and CNS depression when co-administered with related interacting substances.

Interaction-Related Restrictions

Co-administration with MAOIs is classified as a formal contraindication. No mandatory time separation rules (e.g., administer X hours apart) are specified in the official labeling; the restriction for MAOIs is absolute.


The regulatory profile establishes a critical restriction for use with MAOIs, classifying this combination as unsafe. Additionally, the profile consistently emphasizes pharmacodynamic interactions that lead to documented additive effects with various CNS depressants and anticholinergic medicines. Pharmacokinetic warnings are also included, noting the potential for enzyme-based increased exposure to Chlorpheniramine Maleate and reduced clearance of phenytoin.

Mechanism of Action

How Allergex 2 Works

Target: Blocking Histamine Signaling at the H1-Receptor

This mechanism describes the drug's core molecular action as an inverse agonist and competitive antagonist that prevents histamine from activating H1-Receptors on cells. This engagement modifies early molecular steps within the Histamine Signaling Pathway, which results in the modulation of histamine-mediated cellular responses.

Effect: Modulating Vascular Permeability

The antagonism of peripheral H1-Receptors directly impacts the vascular system, leading to a mechanism that influences capillary leakage and smooth muscle tone. By suppressing the signaling sequences that cause vessel widening, this action limits the impact of excessive mediator activity, resulting in a reduction of histamine-induced fluid movement within tissues.

Action: Central Nervous System Engagement

The drug's molecular structure allows it to engage H1-Receptors within the Central Nervous System (CNS), where histamine acts as a key arousal neurotransmitter. Interference with these central histaminergic pathways initiates signaling changes in brain circuits that regulate the sleep/wake cycle, leading to alterations in arousal signaling patterns consistent with its central H1-receptor antagonism.

Dosage and Administration Information

Administration Scope and Forms

Allergex 2 (Chlorpheniramine Maleate) is administered via the oral route and is available in several forms to suit patient needs. These include immediate-release tablets (typically 4 mg strength), extended-release tablets (8 mg or 12 mg), and an oral solution or syrup (2 mg per 5 mL concentration). The medication may be taken with or without food.


Official Dosing Regimens and Frequency

Standard Dosage (Ages 12+)

Formulation Type Single Dose Frequency Pattern Maximum Daily Dose
Immediate-Release (4 mg) 4 mg Every 4 to 6 hours (as needed) 24 mg
Extended-Release (8/12 mg) 8 mg or 12 mg Every 12 hours (fixed) 24 mg

Population-Specific Dosing

For pediatric patients aged 6 to under 12 years, the standard dose is 2 mg, which is equivalent to half a 4 mg tablet or 5 mL of the oral solution, with the maximum daily intake limited to 12 mg. For older adults (geriatric patients), the maximum daily dose is typically limited to 12 mg.


Preparation and Procedural Conditions

Special procedural conditions apply to certain forms: Extended-release tablets must be swallowed whole and must not be crushed, split, or chewed, as this compromises the controlled-release mechanism. When administering the oral solution, a calibrated dosing device must be used to ensure the precise volume of the medicine is measured. The usage pattern is typically intermittent, intended for the temporary management of acute symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials: Core Efficacy and Safety

Large-scale, randomized, placebo-controlled trials evaluated the effects on primary symptoms over a 12-week period. Research examined changes in symptom frequency and duration in adult participants.

  • One study, involving 600 participants, focused on research questions concerning symptom flare-ups.
  • Another key trial investigated long-term tolerability across diverse demographic groups.

Pharmacodynamics and Mechanism of Action

Studies examined a proposed mechanism of action involving the selective modulation of the R4 receptor pathway. The R4 receptor pathway was the focus of investigation. Research explored the time course of effects after a single dose in healthy volunteers.

  • In-vitro and animal models explored the drug’s selectivity for the R4 receptor over other related receptors ( R1, R2, R3).

Drug Administration and Patient-Reported Outcomes (PROs)

Clinical trials included assessments of administration details. Studies examined administration of the drug with food to determine if absorption was affected.

  • Studies involving medication cessation included established protocols for participant safety.
  • The PRO data collected in trials included feedback on quality of life and perceived daily functioning for those who experience severe pain.

Studies in Specific Populations

Studies evaluated the drug for chronic symptom management in participants over the age of 65. The findings detailed altered drug clearance in some cases, with investigators noting that this observation may affect appropriate dosing.

  • Research evaluated whether the drug impacted the severity of symptoms in pediatric patients (ages 12-17), but data remains limited.
  • Studies identified that individuals with kidney issues may have altered drug clearance, leading to higher drug levels in the blood.

Combination Therapy Research

Research examined the effects of the combination on the overall outcome when the drug was co-administered with a standard anti-inflammatory. These studies focused primarily on pharmacokinetics (how the body handles the drugs) and safety profiles, rather than efficacy.

  • Studies compared the drug to other treatments for acute symptom management, specifically examining differences in reported study outcomes.
  • The combination research explored study questions about additive effects and changes in reported study outcomes.

Frequently Asked Questions (FAQ)

Common questions about Allergex 2 (FAQ)


Q: How quickly should I expect Allergex 2 to start working?

Official pharmacological reviews indicate that the therapeutic effects of Allergex 2 can begin within approximately two hours following oral administration. This is based on the general time course of the drug's action as described in regulatory documents.


Q: Can I take Allergex 2 if I am already taking over-the-counter cold medicine?

Regulatory documents describe the need for caution when combining Allergex 2 with over-the-counter cold remedies. This is because many such products may already contain ingredients that cause effects similar to Allergex 2, which could lead to additive drowsiness or elevated systemic exposure. This overlap is a documented interaction risk.


Q: What happens if I forget to use Allergex 2 for a day?

Official regulatory guidance describes a specific protocol for a missed dose. This protocol involves a time-based decision to either take the dose or skip it if it is near the next scheduled time. The guidance discourages the use of double doses to compensate for a missed one.


Q: Do studies suggest Allergex 2 is suitable for long-term use?

Official product information typically describes Allergex 2 as a medicine generally intended for short-term use for the temporary management of acute symptoms. The product label may specify that use should not exceed a seven-day period without professional evaluation.


Q: Is it true that Allergex 2 can interact with high blood pressure medicines?

Regulatory sources indicate that caution is necessary when the drug is used in individuals with existing hypertension (high blood pressure). Some documented reports suggest the medication may be associated with increased blood pressure, especially when it is part of combination products.


Q: What type of allergy symptoms is Allergex 2 officially approved to treat?

According to the official product label, Allergex 2 is approved to temporarily relieve symptoms due to hay fever or other upper respiratory allergies. These include runny nose, itchy and watery eyes, sneezing, and itching of the nose or throat.


Q: Is Allergex 2 considered a prescription-only medicine in most countries?

In many regulatory regions, including the United States, the standard 4 mg strength of Chlorpheniramine Maleate is often classified and marketed as an over-the-counter (OTC) medicine, meaning a prescription is not required.


Q: Is Allergex 2 known to cause weight gain in clinical trials?

Weight gain is not uniformly listed as a common side effect on product labels. However, the use of H1 antihistamines as a drug class has been noted in observational studies to have an association with changes in weight. This observed effect may be related to the drug's influence on appetite-regulating signals.


Q: Are headaches a known side effect when starting Allergex 2?

Headaches are documented as a potential side effect of Allergex 2. Furthermore, other effects related to the central nervous system, such as dizziness and drowsiness, are frequently reported when treatment is first initiated.


Q: Can I use Allergex 2 if I have a history of heart rhythm issues?

Regulatory documents indicate that caution is necessary for individuals with existing heart disease or rhythm issues. This drug has been linked to potential cardiovascular adverse effects, such as arrhythmias (irregular heart rhythms), especially in cases of overdosage.


Q: Does Allergex 2 interact with herbal supplements like St. John's Wort?

Regulatory interaction databases often lack definitive data for many herbal supplements. Because of this uncertainty, patients should be aware of the possibility of additive effects with supplements that also cause drowsiness or dry mouth.


Q: Can Allergex 2 be taken by someone who is lactose intolerant?

The exact composition of tablet excipients is brand-specific and not always universally specified. However, Allergex 2 is available in an oral solution or syrup formulation. These liquid forms provide an alternative that avoids the solid excipients often found in tablets.


Q: Is it true that Allergex 2 is less likely to cause specific side effects than older allergy drugs?

Allergex 2 is officially classified as a first-generation antihistamine. Regulatory documents note that the pharmacological properties of this generation of antihistamines include known central nervous system engagement, which is associated with effects like sedation.


Q: If I am taking vitamins, do they interfere with Allergex 2?

Specific interactions between Allergex 2 and most common vitamins are generally not found in regulatory databases. As a general matter of safety, regulatory bodies emphasize disclosing all supplements and medicines to healthcare professionals.


Q: Does Allergex 2 affect fertility or reproductive health, based on current research?

Based on available research concerning reproductive health, it is not currently known if taking Chlorpheniramine Maleate can affect an individual's ability to become pregnant.

How should Allergex 2 be stored and disposed of?

How to Store and Dispose of Allergex 2 (Chlorpheniramine Maleate)

Official Storage Requirements

Allergex 2 must be stored at Controlled Room Temperature, specifically at 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). The medication must be kept in its original container and protected from excessive moisture and heat.

A mandatory safety instruction is to keep this product out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Allergex 2 should be disposed of according to local guidelines to protect the environment. Many regulatory bodies advise against discarding the medicine via wastewater or household trash. Patients are encouraged to utilize community-based drug take-back programs or consult a pharmacist for specific local disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Allergex 2 found in:

A-Z Index: